Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.19 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Quick Ratio than Neogen in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 3377 to 3421.

Explain Quick Ratio?
How much Cash & cash equivalents NEOG�s has?
What are NEOG�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NEOG/financial-strength

https://api.csimarket.com/api/v1/companies/NEOG/fundamentals

https://api.csimarket.com/api/v1/companies/NEOG/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NEOG Quick Ratio	(Aug 31 2026) Q1	(May 31 2026) Q4	(Feb 28 2026) Q3	(Nov 30 2025) Q2	(Aug 31 2025) Q1
Y / Y Current Liabilities Change	514.96 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	23.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.19	Subscribe	Subscribe	Subscribe	Subscribe
NEOG's Total Ranking	# 3421	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-2.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-7.28 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 13
Healthcare Sector	# 827
Overall Market	# 3421

Quick Ratio Statistics
High	Average	Low
8.38	4.11	0.19
(Feb 29 2020)		(Aug 31 2026)

Financial Statements
Neogen's Current Liabilities	$ 899 Millions	Visit NEOG's Balance sheet
Neogen's Cash & cash equivalent	$ 172 Millions	Visit NEOG's Balance sheet
Source of NEOG's Sales		Visit NEOG's Sales by Geography

Cumulative Neogen's Quick Ratio

NEOG's Quick Ratio for the trailling 12 Months

NEOG Quick Ratio	(Aug 31 2026) 12 Months	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	373.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	23.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.23	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3955	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	35.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	5.26 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NEOG Financial Strength Comparisons >> Go to Compare NEOG Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $899.10 millions, cumulative Quick Ratio decreased to 0.23 below the Neogen Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Neogen. While Quick Ratio overall ranking has improved so far to 3955, from total ranking during the twelve months ending fourth quarter 2026 at 3959.

Explain Quick Ratio?
How much Cash & cash equivalents NEOG�s has?
What are NEOG�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 893
Within the Market	# 3955

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.43	1.64	0.8
(May 31 2013)		(Feb 28 2023)

Companies with similar Quick Ratio in the quarter ending Aug 31 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Aug 31 2026 MRQ Cash & cash equivalent	Aug 31 2026 MRQ Current Liabilities
Neogen Corporation	0.19	$ 172.000 Millions	$ 899.100 Millions
Idexx Laboratories Inc	0.16	$ 197.536 Millions	$ 1,264.222 Millions
Quidelortho Corp	0.16	$ 166.400 Millions	$ 1,067.100 Millions

Date modified: 2026-10-08T04:22:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.